Journal Watch · Frontiers in Immunology · 2026

The value of Protein Phosphatase Methylesterase 1 in diagnosis, prognosis and immunoregulation: from pan-cancer analysis to breast cancer verification.

Functional experiments revealed that suppression of PPME1 significantly inhibits the migration, invasion, and tumor growth of breast cancer cells, suggesting that PPME1 may serve as a potential therapeutic target for breast cancer progression.<h4>Conclusions</h4>Overall, our data indicate that PPME1 acts as an oncogenic driver in multiple cancer types, promoting BRCA progression by enhancing pro-tumorigenic pathways.

Wang Y, Zhang Y, Li Y et al.Frontiers in Immunology4 min readPharma relevance 50/100

DOI: 10.3389/fimmu.2026.1770711PMID: 41884849Study type: preclinical (animal / model) study

TL;DR

Functional experiments revealed that suppression of PPME1 significantly inhibits the migration, invasion, and tumor growth of breast cancer cells, suggesting that PPME1 may serve as a potential therapeutic target for breast cancer progression.<h4>Conclusions</h4>Overall, our data indicate that PPME1 acts as an oncogenic driver in multiple cancer types, promoting BRCA progression by enhancing pro-tumorigenic pathways.

Key findings

  • Functional enrichment analysis indicates PPME1's involvement in DNA damage and repair, pathway activation, substance metabolism, protein modification, and immune regulation.
  • In breast cancer, PPME1 mRNA and protein levels are elevated in tumor tissues compared to adjacent normal tissue.
  • Functional experiments revealed that suppression of PPME1 significantly inhibits the migration, invasion, and tumor growth of breast cancer cells, suggesting that PPME1 may serve as a potential therapeutic target for breast cancer progression.<h4>Conclusions</h4>Overall, our data indicate that PPME1 acts as an oncogenic driver in multiple cancer types, promoting BRCA progression by enhancing pro-tumorigenic pathways.

What they did

The role of PPME1 in tumor progression was evaluated <i>in vitro</i> using CCK-8, colony formation, wound healing, and Matrigel transwell assays, and <i>in vivo</i> using xenograft tumor models.<h4>Results</h4>Our pan-cancer analysis demonstrates that PPME1 is upregulated in the majority of tumors and exhibits heterogeneous expression across immune and molecular subtypes. Elevated levels of PPME1 constitute an independent risk factor in various cancers, including BLCA, BRCA, HNSC, KICH, LIHC, and UVM, and are associated with a poor prognosis. It has moderate to high diagnostic accuracy and can impact the tumor microenvironment by modifying genomic stability, affecting immunotherapy outcomes, and altering the immune response from anti-tumor to tumor-promoting.

Full abstract (original)

Background: <h4>Background</h4>The Protein Phosphatase Methylesterase 1 (PPME1) is a methylesterase specific to phosphatase 2A, a tumor suppressor, and plays a key role in tumor development. Its impact on pan-cancer diagnosis, prognosis, and immune regulation is still uncertain.<h4>Methods</h4>We analyzed PPME1 expression across multiple carcinomas using TCGA, GEO, and other datasets, focusing on its transcriptional profile, prognostic value, genetic and epigenetic alterations, and immunological role. To substantiate our findings, we evaluated PPME1 expression and protein levels in breast cancer tissues through RT-qPCR, Western blotting, and immunohistochemical techniques.

What they did: The role of PPME1 in tumor progression was evaluated <i>in vitro</i> using CCK-8, colony formation, wound healing, and Matrigel transwell assays, and <i>in vivo</i> using xenograft tumor models.<h4>Results</h4>Our pan-cancer analysis demonstrates that PPME1 is upregulated in the majority of tumors and exhibits heterogeneous expression across immune and molecular subtypes. Elevated levels of PPME1 constitute an independent risk factor in various cancers, including BLCA, BRCA, HNSC, KICH, LIHC, and UVM, and are associated with a poor prognosis. It has moderate to high diagnostic accuracy and can impact the tumor microenvironment by modifying genomic stability, affecting immunotherapy outcomes, and altering the immune response from anti-tumor to tumor-promoting.

Results & conclusions: Functional enrichment analysis indicates PPME1's involvement in DNA damage and repair, pathway activation, substance metabolism, protein modification, and immune regulation. In breast cancer, PPME1 mRNA and protein levels are elevated in tumor tissues compared to adjacent normal tissue. Functional experiments revealed that suppression of PPME1 significantly inhibits the migration, invasion, and tumor growth of breast cancer cells, suggesting that PPME1 may serve as a potential therapeutic target for breast cancer progression.<h4>Conclusions</h4>Overall, our data indicate that PPME1 acts as an oncogenic driver in multiple cancer types, promoting BRCA progression by enhancing pro-tumorigenic pathways.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1770711 · PubMed 41884849.

Why it matters for pharma & biotech

  • Directly relevant to teams in mRNA / delivery technology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: mRNA / delivery technology

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Frontiers in Immunology study find?

Functional experiments revealed that suppression of PPME1 significantly inhibits the migration, invasion, and tumor growth of breast cancer cells, suggesting that PPME1 may serve as a potential therapeutic target for breast cancer progression.<h4>Conclusions</h4>Overall, our data indicate that PPME1 acts as an oncogenic driver in multiple cancer types, promoting BRCA progression by enhancing pro-tumorigenic pathways.

What type of study is this?

It is a preclinical (animal / model) study, published in Frontiers in Immunology in 2026. The role of PPME1 in tumor progression was evaluated <i>in vitro</i> using CCK-8, colony formation, wound healing, and Matrigel transwell assays, and <i>in vivo</i> using xenograft tumor models.<h4>Results</h4>Our pan-cancer analysis demonstrates that PPME1 is upregulated in the majority of tumors and exhibits heterogeneous expression across immune and molecular subtypes.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1770711. PubMed ID: 41884849. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Wang Y, Zhang Y, Li Y et al.. The value of Protein Phosphatase Methylesterase 1 in diagnosis, prognosis and immunoregulation: from pan-cancer analysis to breast cancer verification.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1770711.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/the-value-of-protein-phosphatase-methylesterase-1-in-diagnosis-prognosis-770711/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides